



## PET Imaging in Prostate Cancer

Guest Editors:

**Prof. Dr. Francesco Ceci**

Division of Nuclear Medicine,  
European Institute of Oncology  
(IEO), IRCCS, Via Ripamonti 435,  
20141 Milan, Italy

**Dr. Giulia Marvaso**

Department of Radiotherapy,  
European Institute of Oncology  
(IEO) IRCCS, 20141 Milan, Italy

Deadline for manuscript  
submissions:

**31 January 2025**

### Message from the Guest Editors

Dear Colleagues,

The introduction of molecular imaging, namely positron emission tomography (PET) imaging, in prostate cancer has already changed the clinical outcomes and therapeutic management of patients. PET imaging has proved to have higher diagnostic accuracy compared to conventional imaging, especially for staging high-risk patients and identifying metastatic locations in the case of disease recurrence. Several PET radiopharmaceuticals have been proposed over the last decade, and these diagnostic techniques are now currently placed under the umbrella term “new-generation imaging”.

This Special Issue aims to collect original articles and reviews on the role of PET imaging in prostate cancer, with a special focus on innovative approaches and translational imaging.

Prof. Dr. Francesco Ceci

Dr. Giulia Marvaso

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)